Center for Musculoskeletal Research, University of Rochester Medical Center, Rochester, New York, USA.
Department of Orthopaedics and Rehabilitation, University of Rochester Medical Center, Rochester, New York, USA.
J Orthop Res. 2023 Nov;41(11):2384-2393. doi: 10.1002/jor.25564. Epub 2023 Apr 8.
While recent studies showed that macrophages are critical for bone fracture healing, and lack of M2 macrophages have been implicated in models of delayed union, functional roles for specific M2 receptors have yet to be defined. Moreover, the M2 scavenger receptor CD163 has been identified as a target to inhibit sepsis following implant-associated osteomyelitis, but potential adverse effects on bone healing during blockage therapy have yet to be explored. Thus, we investigated fracture healing in C57BL/6 versus CD163 mice using a well-established closed, stabilized, mid-diaphyseal femur fracture model. While gross fracture healing in CD163 mice was similar to that of C57BL/6, plain radiographs revealed persistent fracture gaps in the mutant mice on Day 14, which resolved by Day 21. Consistently, 3D vascular micro-CT demonstrated delayed union on Day 21, with reduced bone volume (74%, 61%, and 49%) and vasculature (40%, 40%, and 18%) compared to C57BL/6 on Days 10, 14, and 21 postfracture, respectively (p < 0.01). Histology confirmed large amounts of persistent cartilage in CD163 versus C57BL/6 fracture callus on Days 7 and 10 that resolves over time, and immunohistochemistry demonstrated deficiencies in CD206 M2 macrophages. Torsion testing of the fractures confirmed the delayed early union in CD163 femurs, which display decreased yield torque on Day 21, and a decreased rigidity with a commensurate increase in rotation at yield on Day 28 (p < 0.01). Collectively, these results demonstrate that CD163 is required for normal angiogenesis, callus formation, and bone remodeling during fracture healing, and raise potential concerns about CD163 blockade therapy.
虽然最近的研究表明巨噬细胞对于骨折愈合至关重要,并且缺乏 M2 巨噬细胞与延迟愈合模型有关,但特定 M2 受体的功能作用仍有待确定。此外,M2 清道夫受体 CD163 已被确定为抑制与植入物相关骨髓炎后败血症的靶点,但在阻断治疗期间对骨愈合的潜在不利影响尚未得到探索。因此,我们使用已建立的闭合、稳定、中干股骨干骨折模型,研究了 C57BL/6 与 CD163 小鼠的骨折愈合情况。虽然 CD163 小鼠的大体骨折愈合与 C57BL/6 相似,但平片显示在突变小鼠中第 14 天仍存在持续的骨折间隙,第 21 天消失。一致地,3D 血管微 CT 显示第 21 天延迟愈合,与 C57BL/6 相比,骨折后第 10、14 和 21 天的骨体积分别减少 74%、61%和 49%(p < 0.01)和血管分别减少 40%、40%和 18%。组织学证实 CD163 骨折痂中的软骨量在第 7 和 10 天比 C57BL/6 多,随着时间的推移会消失,免疫组织化学显示 CD206 M2 巨噬细胞缺陷。骨折的扭转试验证实了 CD163 股骨的早期延迟愈合,CD163 股骨在第 21 天的屈服扭矩降低,并且在第 28 天的屈服刚性降低,同时旋转增加(p < 0.01)。总的来说,这些结果表明 CD163 对于骨折愈合过程中的正常血管生成、骨痂形成和骨重塑是必需的,并提出了对 CD163 阻断治疗的潜在担忧。